Protein Binding and Stability of Drug Candidates: The Achilles’ Heel in In Vitro Potency Assays
Tóm tắt
In the present scenario of drug discovery, several screening filters ensure a rigorous nomination of clinical candidates. One of these screens is the determination of IC50, the concentration of drug at half-maximal inhibitory concentration, also known as a potency assay. However, various nuances pertaining to the design, execution, and interpretation of in vitro potency results suggest a sizeable opportunity for the generation of erroneous data. The focus areas of this article include: (1) examining the requirement for the addition of serum albumin in in vitro potency assays, (2) problems encountered with cell lysates, and (3) drug candidate stability concerns during in vitro potency assays/high-throughput screening. Based on this assessment, the interpretation of the data generated using cell-based systems (i.e., lysates with or without the addition of fetal bovine serum) should be carried out with caution for in vitro potency testing, and the inclusion of a correction factor for non-specific protein binding should be considered. The addition of serum albumin to a cell-free system should be restricted to drugs having high protein binding (≥ 90%). Additionally, stability assessment of analytes should be considered to avoid dubious in vitro potency outcomes due to degraded material or active metabolite(s).
Tài liệu tham khảo
Valko K, Nunhuck S, Bevan C, Abraham MH, Reynolds DP. Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol/water and immobilized artificial membrane lipophilicity. J Pharm Sci. 2003;92:2236–48. https://doi.org/10.1002/jps.10494.
Gleeson MP. Plasma protein binding affinity and its relationship to molecular structure: an in silico analysis. J Med Chem. 2007;50:101–12. https://doi.org/10.1021/jm060981b.
Liu X, Wright M, Hop CE. Rational use of plasma protein and tissue binding data in drug design. J Med Chem. 2014;57:8238–48. https://doi.org/10.1021/jm5007935.
Brunton L, Lazo J, Parker K. Goodman & Gilman’s the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill; 2006.
Liu X, Chen C. Strategies to optimize brain penetration in drug discovery. Curr Opin Drug Discov Dev. 2005;8:505–12.
Trainor G. The importance of plasma protein binding in drug discovery. Expert Opin Drug Discov. 2007;2:51–64. https://doi.org/10.1517/17460441.2.1.51.
Hammarlund-Udenaes M, Friden M, Syvanen S, Gupta A. On the rate and extent of drug delivery to the brain. Pharm Res. 2008;25:1737–50. https://doi.org/10.1007/s11095-007-9502-2.
Lin JH. CSF as a surrogate for assessing CNS exposure: an industrial perspective. Curr Drug Metab. 2008;9:46–59. https://doi.org/10.2174/138920008783331077.
Schmidt S, Gonzalez D, Derendorf H. Significance of protein binding in pharmacokinetics and pharmacodynamics. J Pharm Sci. 2010;99:1107–22. https://doi.org/10.1002/jps.21916.
Smith DA, Di L, Kerns EH. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov. 2010;9:929–39. https://doi.org/10.1038/nrd3287.
Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002;71:115–21. https://doi.org/10.1067/mcp.2002.121829.
Lin JH, Lu AYH. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev. 1997;49:403–49.
Fessey RE, Austin RP, Barton P, Davis AM, Wenlock MC. The role of plasma protein binding in drug discovery. In: Testa B, editor. Pharmacokinetic profiling in drug research: biological, physicochemical, and computational strategies. Zurich: Helvetica Chimica Acta; 2006. p. 119–41.
Wan H, Rehngren M, Giordanetto F, Bergstroem F, Tunek A. High-throughput screening of drug–brain tissue binding and in silico prediction for assessment of central nervous system drug delivery. J Med Chem. 2007;50:4606–15. https://doi.org/10.1021/jm070375w.
Lewis DFV, Jacobs MN, Dickins M. Compound lipophilicity for substrate binding to human P450s in drug metabolism. Drug Discov Today. 2004;9:530–7. https://doi.org/10.1016/S1359-6446(04)03115-0.
Reichel A. Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept. Chem Biodivers. 2009;6:2030–49. https://doi.org/10.1002/cbdv.200900103.
Kebebew E, Ghosh C, Kumar S, et al. A combinatorial strategy for targeting BRAF V600E mutant cancers with BRAF V600E inhibitor (PLX4720) and tyrosine kinase inhibitor (ponatinib). Clin Cancer Res. 2020. https://doi.org/10.1158/1078-0432.
Du G, Rao S, Gurbani D, et al. Structure-based design of a potent and selective covalent inhibitor for SRC kinase that targets a p-Loop cysteine. J Med Chem. 2020. https://doi.org/10.1021/acs.jmedchem.9b01502.
Estrada-Valencia M, Herrera-Arozamena C, Pérez C, et al. New flavonoid-N, N-dibenzyl(N-methyl)amine hybrids: multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties. J Enzyme Inhib Med Chem. 2019;34:712–27. https://doi.org/10.1080/14756366.2019.1581184.
Kumar A, Henry RJ, Stoica BA, et al. Neutral sphingomyelinase inhibition alleviates LPS-induced microglia activation and neuroinflammation after experimental traumatic brain injury. J Pharmacol Exp Ther. 2019;368(3):338–52. https://doi.org/10.1124/jpet.118.253955.
Marchesini N, Osta W, Bielawski J, Luberto C, Obeid LM, Hannun YA. Role for mammalian neutral sphingomyelinase 2 in confluence-induced growth arrest of MCF7 cells. J Biol Chem. 2004;279:25101–11. https://doi.org/10.1074/jbc.M313662200.
Back MJ, Ha HC, Fu Z, et al. Activation of neutral sphingomyelinase 2 by starvation induces cell-protective autophagy via an increase in Golgi-localized ceramide. Cell Death Dis. 2018;9:670. https://doi.org/10.1038/s41419-018-0709-4.
Filosto S, Fry W, Knowlton AA, Goldkorn T. Neutral sphingomyelinase 2 (nSMase2) is a phosphoprotein regulated by calcineurin (PP2B). J Biol Chem. 2010;285:10213–22. https://doi.org/10.1074/jbc.M109.069963.
Okazaki T, Bielawska A, Domae N, Bell RM, Hannun YA. Characteristics and partial purification of a novel cytosolic, magnesium-independent, neutral sphingomyelinase activated in the early signal transduction of 1 alpha,25-dihydroxyvitamin D3-induced HL-60 cell differentiation. J Biol Chem. 1994;269:4070–7.
Lawler JF Jr, Yin M, Diehl AM, Roberts E, Chatterjee S. Tumor necrosis factor-alpha stimulates the maturation of sterol regulatory element binding protein-1 in human hepatocytes through the action of neutral sphingomyelinase. J Biol Chem. 1998;273:5053–9. https://doi.org/10.1074/jbc.273.9.5053.
Kalvass JC, Maurer TS. Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos. 2002;23:327–38. https://doi.org/10.1002/bdd.325.
Zeitlinger MA, Derendorf H, Mouton JW, et al. Protein binding: do we ever learn? Antimicrob Agents Chemother. 2011;55:3067–74. https://doi.org/10.1128/AAC.01433-10.
Furbeth M, Adam D. The importance of serum components, particularly complement factors, properdin and transferrin, in inhibition of bacterial growth by human serum. Infection. 1976;4:102–6. https://doi.org/10.1007/bf01638725.
Koets P. The decrease of albumin concentration of human blood serum during heat inactivation. Science. 1952;115:21–2. https://doi.org/10.1126/science.115.2975.21.
Mosley AK, Brouwer KL. Heat treatment of human serum to inactivate HIV does not alter protein binding of selected drugs. Ther Drug Monit. 1997;19:477–9. https://doi.org/10.1097/00007691-199708000-00019.
Webster R, Leishman D, Walker D. Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. Curr Opin Drug Discov Dev. 2002;5:116–26.
Needham LA, Davidson AH, Bawden LJ, et al. Drug targeting to monocytes and macrophages using esterase-sensitive chemical motifs. J Pharmacol Exp Ther. 2011;339:132–42. https://doi.org/10.1124/jpet.111.183640.
Buscher B, Laakso S, Mascher H, et al. Bioanalysis for plasma protein binding studies in drug discovery and drug development: views and recommendations of the European Bioanalysis Forum. Bioanalysis. 2014;6:673–82. https://doi.org/10.4155/bio.13.338.
Xiao JF, Zhou B, Ressom HW. Metabolite identification and quantitation in LC-MS/MS-based metabolomics. Trends Anal Chem. 2012;32:1–14. https://doi.org/10.1016/j.trac.2011.08.009.
Jacobs PL, Ridder L, Ruijken M, et al. Identification of drug metabolites in human plasma and serum integrating metabolite prediction, LC-HRMS and untargeted data processing. Bioanalysis. 2013;5:2115–28. https://doi.org/10.4155/bio.13.178.
Naz S, Gallart-Ayala H, Reinke SN, et al. Development of a liquid chromatography-high resolution mass spectrometry metabolomics method with high specificity for metabolite identification using all ion fragmentation acquisition. Anal Chem. 2017;89:7933–42. https://doi.org/10.1021/acs.analchem.7b00925.
Kerns EH, Di L. Pharmaceutical profiling in drug discovery. Drug Discov Today. 2003;8:316–23. https://doi.org/10.1016/s1359-6446(03)02649-7.
Di L, Kerns EH. Profiling drug-like properties in discovery research. Curr Opin Chem Biol. 2003;7:402–8. https://doi.org/10.1016/s1367-5931(03)00055-3.
Bohnert T, Gan LS. Plasma protein binding: from discovery to development. J Pharm Sci. 2013;102:2953–94. https://doi.org/10.1002/jps.23614.